These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9833163)

  • 21. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T
    Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candesartan in the treatment of hypertension: what have we learnt in the last decade?
    Barrios V; Escobar C
    Expert Opin Drug Saf; 2011 Nov; 10(6):957-68. PubMed ID: 21848481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
    Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
    Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
    Mugellini A; Nieswandt V
    Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
    Sidorenko BA; Preobrazhenskiĭ DV; Soplevenko AV; Ivanova NA; Stetsenko TM
    Kardiologiia; 2004; 44(1):55-65. PubMed ID: 15029149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report.
    Hoy SM; Keating GM
    Paediatr Drugs; 2012 Feb; 14(1):61-2. PubMed ID: 22149551
    [No Abstract]   [Full Text] [Related]  

  • 32. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
    Sever P; Holzgreve H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S69-73. PubMed ID: 9331014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
    Weir MR; Weber MA; Neutel JM; Vendetti J; Michelson EL; Wang RY
    Am J Hypertens; 2001 Jun; 14(6 Pt 1):567-72. PubMed ID: 11411737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.
    Gradman AH; Lewin A; Bowling BT; Tonkon M; Deedwania PC; Kezer AE; Hardison JD; Cushing DJ; Michelson EL
    Heart Dis; 1999; 1(2):52-7. PubMed ID: 11720604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharma-clinics. The drug of the month. Candesartan (Atacand)].
    Kulbertus H
    Rev Med Liege; 1999 Jun; 54(6):557-60. PubMed ID: 10446528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen: results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial.
    Sun Y; Liao Y; Yuan Y; Feng L; Ma S; Wei F; Wang M; Zhu F
    J Am Soc Hypertens; 2014 Jan; 8(1):21-7. PubMed ID: 24131669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.